# XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma

> **NCT03599778** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Anhui Provincial Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Gastric Carcinoma

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03599778
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03599778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03599778, "XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03599778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*